Mclelland J, Fisher C, Farr P M, Diffey B L, Cox N H
University Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, U.K.
Br J Dermatol. 1991 Jun;124(6):585-90. doi: 10.1111/j.1365-2133.1991.tb04956.x.
The plasma 8-methoxypsoralen (8-MOP) concentration was measured in 60 patients commencing psoralen photochemotherapy (PUVA). At the time of blood sampling each patient was phototested using a series of 10 exposures to UVA. The resulting erythema was measured objectively 72 h after irradiation and dose-response curves for psoralen-UVA erythema were constructed. Although the dose of 8-MOP was calculated according to body weight, patients receiving 30 mg of 8-MOP had a significantly lower mean plasma concentration than those receiving higher doses. There was no significant correlation between plasma 8-MOP concentration and minimal phototoxic dose, either estimated visually or calculated from the dose-response curves. However the slope of the dose-response curve showed significant correlation with plasma 8-MOP concentration. The variation between patients in the rate of increase of the erythemal response, but not the variation in threshold sensitivity, can be explained by difference in plasma psoralen concentration.
对60名开始补骨脂素光化学疗法(PUVA)的患者测量了血浆8-甲氧基补骨脂素(8-MOP)浓度。在采血时,对每位患者进行了一系列10次UVA照射的光试验。照射后72小时客观测量产生的红斑,并构建补骨脂素-UVA红斑的剂量反应曲线。尽管8-MOP的剂量是根据体重计算的,但接受30mg 8-MOP的患者的平均血浆浓度明显低于接受更高剂量的患者。血浆8-MOP浓度与最小光毒性剂量之间没有显著相关性,无论是通过视觉估计还是根据剂量反应曲线计算。然而,剂量反应曲线的斜率与血浆8-MOP浓度显示出显著相关性。患者之间红斑反应增加率的差异,而非阈值敏感性的差异,可以用血浆补骨脂素浓度的差异来解释。